Bronchial carcinoma: Added benefit of crizotinib not proven
Since August 2016 crizotinib (trade name: Xalkori) has also been available for adults with advanced non-small cell lung cancer (NSCLC) in whom the structure of the enzyme "proto-oncogene tyrosine-protein kinase" (ROS1) is altered in the tumour tissue. In an early benefit assessment the German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether this drug offers advantages for patients over the appropriate comparator therapies. According to the findings, such an added benefit is not proven: for one patient group, the dossier does not contain any data at all; for two further groups, the data are unsuitable for assessment.

Read more at: http://medicalxpress.com/news/2017-01-bronchial-carcinoma-added-benefit-crizotinib.html#jCp
Like
Comment
Share